Navigation Links
OHSU study says stem cell 'fusion' occurs in tumors

turning over damaged tissue, or may even be implicated in disease progression.

"The intestinal lining is the protective barrier between your body and the outside environment. Therefore, it sees all of the offensive contaminants that you ingest, from the beer you drink to the charbroiled hamburger you eat, that can induce mutations in the cells. The gut protects itself by rapidly turning over its epithelial cells. Plus, when there is damage to the surface lining, it is critical that regeneration and reestablishment of the barrier occurs rapidly. We think that cell fusion with bone marrow cells is the body's way of jump-starting that regeneration of the epithelium," she said.


'"/>

Source:Oregon Health & Science University


Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2Princeton scientists find way to catalog all that goes wrong in a cancer cell 2Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 1Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 1Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 1New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 2New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 4New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 5New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 6New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 7New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 8New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 9New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 10
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4
Other Biology Technology:Shire's New Product Portfolio Delivers Strong Quarterly Performance 2Shire's New Product Portfolio Delivers Strong Quarterly Performance 3Shire's New Product Portfolio Delivers Strong Quarterly Performance 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 6Shire's New Product Portfolio Delivers Strong Quarterly Performance 7Shire's New Product Portfolio Delivers Strong Quarterly Performance 8Shire's New Product Portfolio Delivers Strong Quarterly Performance 9Shire's New Product Portfolio Delivers Strong Quarterly Performance 10Shire's New Product Portfolio Delivers Strong Quarterly Performance 11Shire's New Product Portfolio Delivers Strong Quarterly Performance 12Shire's New Product Portfolio Delivers Strong Quarterly Performance 13Shire's New Product Portfolio Delivers Strong Quarterly Performance 14Shire's New Product Portfolio Delivers Strong Quarterly Performance 15Shire's New Product Portfolio Delivers Strong Quarterly Performance 16Shire's New Product Portfolio Delivers Strong Quarterly Performance 17Shire's New Product Portfolio Delivers Strong Quarterly Performance 18Shire's New Product Portfolio Delivers Strong Quarterly Performance 19Shire's New Product Portfolio Delivers Strong Quarterly Performance 20Shire's New Product Portfolio Delivers Strong Quarterly Performance 21Shire's New Product Portfolio Delivers Strong Quarterly Performance 22Shire's New Product Portfolio Delivers Strong Quarterly Performance 23Shire's New Product Portfolio Delivers Strong Quarterly Performance 24Shire's New Product Portfolio Delivers Strong Quarterly Performance 25Shire's New Product Portfolio Delivers Strong Quarterly Performance 26Shire's New Product Portfolio Delivers Strong Quarterly Performance 27Shire's New Product Portfolio Delivers Strong Quarterly Performance 28Shire's New Product Portfolio Delivers Strong Quarterly Performance 29Shire's New Product Portfolio Delivers Strong Quarterly Performance 30Shire's New Product Portfolio Delivers Strong Quarterly Performance 31Shire's New Product Portfolio Delivers Strong Quarterly Performance 32Shire's New Product Portfolio Delivers Strong Quarterly Performance 33Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Sinovac to Participate in Two Upcoming Investor Conferences 2